SCH-58261

From Wikipedia, the free encyclopedia
Jump to: navigation, search
SCH-58261
SCH-58261 structure.png
Systematic (IUPAC) name
5-Amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine
Clinical data
Legal status
  • Uncontrolled
Identifiers
CAS number 160098-96-4 N
ATC code None
PubChem CID 176408
IUPHAR ligand 403
ChemSpider 153647 YesY
ChEMBL CHEMBL17127 YesY
Chemical data
Formula C18H15N7O 
Mol. mass 345.357 g/mol
 N (what is this?)  (verify)

SCH-58261 is a drug which acts as a potent and selective antagonist for the adenosine receptor A2A, with more than 50x selectivity for A2A over other adenosine receptors.[1] It has been used to investigate the mechanism of action of caffeine, which is a mixed A1 / A2A antagonist, and has shown that the A2A receptor is primarily responsible for the stimulant effects of caffeine, but blockade of both A1 and A2A receptors is required to accurately replicate caffeine's effects in animals.[2][3][4][5] SCH-58261 has also shown antidepressant[6] and neuroprotective effects in a variety of animal models,[7][8][9][10][11] and has been investigated as a possible treatment for Parkinson's disease.[12][13]

See also[edit]

References[edit]

  1. ^ Zocchi C, Ongini E, Conti A, Monopoli A, Negretti A, Baraldi PG, Dionisotti S (February 1996). "The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2a adenosine receptor antagonist". The Journal of Pharmacology and Experimental Therapeutics 276 (2): 398–404. PMID 8632302. 
  2. ^ Svenningsson P, Nomikos GG, Ongini E, Fredholm BB (August 1997). "Antagonism of adenosine A2A receptors underlies the behavioural activating effect of caffeine and is associated with reduced expression of messenger RNA for NGFI-A and NGFI-B in caudate-putamen and nucleus accumbens". Neuroscience 79 (3): 753–64. doi:10.1016/S0306-4522(97)00046-8. PMID 9219939. 
  3. ^ Popoli P, Reggio R, Pèzzola A, Fuxe K, Ferré S (July 1998). "Adenosine A1 and A2A receptor antagonists stimulate motor activity: evidence for an increased effectiveness in aged rats". Neuroscience Letters 251 (3): 201–4. doi:10.1016/S0304-3940(98)00533-3. PMID 9726378. 
  4. ^ El Yacoubi M, Ledent C, Ménard JF, Parmentier M, Costentin J, Vaugeois JM (April 2000). "The stimulant effects of caffeine on locomotor behaviour in mice are mediated through its blockade of adenosine A(2A) receptors". British Journal of Pharmacology 129 (7): 1465–73. doi:10.1038/sj.bjp.0703170. PMC 1571962. PMID 10742303. 
  5. ^ Kuzmin A, Johansson B, Gimenez L, Ogren SO, Fredholm BB (February 2006). "Combination of adenosine A1 and A2A receptor blocking agents induces caffeine-like locomotor stimulation in mice". European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology 16 (2): 129–36. doi:10.1016/j.euroneuro.2005.07.001. PMID 16054807. 
  6. ^ El Yacoubi M, Costentin J, Vaugeois JM (December 2003). "Adenosine A2A receptors and depression". Neurology 61 (11 Suppl 6): S82–7. doi:10.1212/01.WNL.0000095220.87550.F6. PMID 14663017. 
  7. ^ Monopoli A, Lozza G, Forlani A, Mattavelli A, Ongini E (December 1998). "Blockade of adenosine A2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats". NeuroReport 9 (17): 3955–9. doi:10.1097/00001756-199812010-00034. PMID 9875735. 
  8. ^ Popoli P, Pintor A, Domenici MR, Frank C, Tebano MT, Pèzzola A, Scarchilli L, Quarta D, Reggio R, Malchiodi-Albedi F, Falchi M, Massotti M (March 2002). "Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum". Journal of Neuroscience 22 (5): 1967–75. PMID 11880527. 
  9. ^ Melani A, Gianfriddo M, Vannucchi MG, Cipriani S, Baraldi PG, Giovannini MG, Pedata F (February 2006). "The selective A2A receptor antagonist SCH 58261 protects from neurological deficit, brain damage and activation of p38 MAPK in rat focal cerebral ischemia". Brain Research. 1073-1074: 470–80. doi:10.1016/j.brainres.2005.12.010. PMID 16443200. 
  10. ^ Minghetti L, Greco A, Potenza RL, Pezzola A, Blum D, Bantubungi K, Popoli P (May 2007). "Effects of the adenosine A2A receptor antagonist SCH 58621 on cyclooxygenase-2 expression, glial activation, and brain-derived neurotrophic factor availability in a rat model of striatal neurodegeneration". Journal of Neuropathology and Experimental Neurology 66 (5): 363–71. doi:10.1097/nen.0b013e3180517477. PMID 17483693. 
  11. ^ Canas PM, Porciúncula LO, Cunha GM, Silva CG, Machado NJ, Oliveira JM, Oliveira CR, Cunha RA (November 2009). "Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway". Journal of Neuroscience 29 (47): 14741–51. doi:10.1523/JNEUROSCI.3728-09.2009. PMID 19940169. 
  12. ^ Chen JF, Xu K, Petzer JP, Staal R, Xu YH, Beilstein M, Sonsalla PK, Castagnoli K, Castagnoli N, Schwarzschild MA (May 2001). "Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease". Journal of Neuroscience 21 (10): RC143. PMID 11319241. 
  13. ^ Simola N, Fenu S, Baraldi PG, Tabrizi MA, Morelli M (October 2006). "Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson's disease". Journal of the Neurological Sciences 248 (1-2): 48–52. doi:10.1016/j.jns.2006.05.038. PMID 16780890.